Functional and structural evidence of lesion repair after alemtuzumab therapy for MS: a mfVEP and MRI study of the human visual pathway
02 July 2021
The visual pathway is an excellent structure-function platform for testing the efficacy of novel remyelinating therapies for multiple sclerosis. Our latest collaborative research in the field has just been published in JNNP (Journal of Neurology, Neurosurgery and Psychiatry) with our COO and University of Sydney Senior Lecturer Tim Wang as the first author.
For more information on SNAC’s Multimodal Turnkey Central Reading Solution for Phase 2 Remyelination Clinical Trials see: Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy.